Neptune Technologies & Bioressources Inc. and Subsidiary Acasti Pharma Inc. to Host Management Discussion Broadcast at 4:30 p.m.
2010年11月4日 - 5:51AM
Neptune Technologies & Bioressources Inc. ("Neptune")
(Nasdaq:NEPT) (TSX-V:NTB) and its subsidiary, Acasti Pharma Inc.
("Acasti"), will host a management discussion on developments at
Acasti during a November 4th Webex broadcast at 4:30 p.m. Eastern
Daylight Time ("EDT").
Due to technical difficulties, the Webex
broadcast initially scheduled Wednesday, November 3rd at 8:30 a.m.
EDT had to be cancelled, Neptune and Acasti management apologizes
for the inconvenient.
The Webex broadcast is rescheduled at
4:30 p.m. EDT on Thursday November 4th.
Management hosts will be Acasti President, Dr. Tina Sampalis and
Chief Operating Officer, Pierre Lemieux as well as Neptune
Vice-President, Administration & Finance, Andre Godin.
The discussion will centre on:
- Milestones at Acasti since the beginning of operations in
August 2008
- Recent launch of Acasti's new medical food called Onemia ™
- Other related topics.
Viewers can listen in to the Webex broadcast through
their phones while watching the power point presentation
online.
-------------------------------------------------------
To watch the power point presentation on your computer:
-------------------------------------------------------
1. Go to
https://intercallcanada.webex.com/intercallcanada/j.php?ED=147808332&UID=0&RT=NCMxMQ%3D%3D
2. Enter your name and email address.
3. Click "Join Now."
-------------------------------------------------------
TO SUBMIT EMAIL QUESTIONS BEFORE OR DURING THE BROADCAST
SEND AN EMAIL TO:
x.harland@neptunebiotech.com
Please refer to the management discussion broadcast.
-------------------------------------------------------
To listen to the company executives while they go through the
power point:
-------------------------------------------------------
Call-in toll-free number:
1-866-468-0803 (US/Canada)
Call-in number: 1-647-4277545 (US/Canada)
Conference Code: 191 534 7247
-------------------------------------------------------
For assistance
-------------------------------------------------------
1. Go to
https://intercallcanada.webex.com/intercallcanada/mc
2. On the left navigation bar, click "Support."
About Neptune Technologies & Bioressources
Inc.
Neptune is an industry-recognized leader in the innovation,
production and formulation of science-based and clinically proven
novel phospholipid products for the nutraceutical and
pharmaceutical markets. The Company focuses on growing consumer
health markets including cardiovascular, inflammatory and
neurological diseases driven by consumers taking a more proactive
approach to managing health and preventing disease. The Company
sponsors clinical trials aimed to demonstrate its product health
benefits and to obtain regulatory approval for label health claims.
Neptune is continuously expanding its intellectual property
portfolio as well as clinical studies and regulatory approvals.
Neptune's products are marketed and distributed in over 20
countries worldwide. Neptune is the mother company of Acasti and
NeuroBioPharm.
About Acasti Pharma Inc.
Acasti Pharma is developing a product portfolio of proprietary
novel long-chain omega-3 phospholipids. Phospholipids are the
major component of cell membranes and are essential for all vital
cell processes. They are one of the principal constituents of High
Density Lipoprotein (good cholesterol) and, as such, play an
important role in modulating cholesterol efflux. Acasti Pharma's
proprietary novel phospholipids carry and functionalize the
polyunsaturated omega-3 fatty acids EPA and DHA, which have been
shown to have substantial health benefits and which are stabilized
by potent antioxidants. Acasti Pharma is focusing initially on
treatments for chronic cardiovascular conditions within the
over-the-counter, medical food and prescription drug markets.
About NeuroBioPharm Inc.
NeuroBioPharm is pursuing pharmaceutical neurological
applications, and a clinical study for a medical food product with
a multinational partner is already initiated. The development of a
prescription drug candidate is currently in progress. Advanced
clinical development and commercialization is planned to be carried
out with multinational partners.
"Neither Nasdaq nor the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release."
Statements in this press release that are not statements of
historical or current fact constitute "forward-looking statements"
within the meaning of the U.S. Private Securities Litigation
Reform Act of 1995 and Canadian securities laws. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other unknown factors that could cause the
actual results of the Company to be materially different from
historical results or from any future results expressed or implied
by such forward-looking statements. In addition to statements which
explicitly describe such risks and uncertainties, readers are
urged to consider statements labeled with the terms "believes,"
"belief," "expects," "intends," "anticipates," "will," or
"plans" to be uncertain and forward-looking. The forward-looking
statements contained herein are also subject generally to other
risks and uncertainties that are described from time to time in the
Company's reports filed with the Securities and Exchange Commission
and the Canadian securities commissions.
CONTACT: Neptune Technologies & Bioressources Inc.
Andre Godin, V.P. Administration and Finance
+1 450.687.2262
a.godin@neptunebiotech.com
www.neptunebiotech.com
Acasti Pharma Inc.
Tina Sampalis, President
+1 450.686.4555
t.sampalis@acastipharma.com
www.acastipharma.com
CEOcast
Dan Schustack
+1 212-732-4300
dschustack@ceocast.com
www.ceocast.com
Howard Group
Bob Beaty
1 (888) 221-0915
bob@howardgroupinc.com
www.howardgroupinc.com
Neptune Wellness Solutions (NASDAQ:NEPT)
過去 株価チャート
から 6 2024 まで 7 2024
Neptune Wellness Solutions (NASDAQ:NEPT)
過去 株価チャート
から 7 2023 まで 7 2024